<SEC-DOCUMENT>0001683168-22-000553.txt : 20220128
<SEC-HEADER>0001683168-22-000553.hdr.sgml : 20220128
<ACCEPTANCE-DATETIME>20220128142519
ACCESSION NUMBER:		0001683168-22-000553
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220127
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220128
DATE AS OF CHANGE:		20220128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RadNet, Inc.
		CENTRAL INDEX KEY:			0000790526
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				133326724
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33307
		FILM NUMBER:		22567762

	BUSINESS ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025
		BUSINESS PHONE:		3104787808

	MAIL ADDRESS:	
		STREET 1:		1510 COTNER AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMEDEX HEALTH SYSTEMS INC
		DATE OF NAME CHANGE:	19930518

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCC FRANCHISING CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>radnet_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:RDNT="http://radnet.com/20220127">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_RDNT_radnet.com_20220127 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20220127_20220127 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0000790526 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityCentralIndexKey">0000790526</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rdnt-20220127.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-27to2022-01-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000790526</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-27</xbrli:startDate>
        <xbrli:endDate>2022-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 14pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20220127__20220127_zrsrStesVIgk"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of
earliest event reported  <span id="xdx_90F_edei--DocumentPeriodEndDate_c20220127__20220127_zt1QRanrpb62"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">January 27, 2022</ix:nonNumeric></span>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">_______________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90E_edei--EntityRegistrantName_c20220127__20220127_zskQEOhPfr1g"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityRegistrantName">RadNet, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<hr style="border-width: 0; color: Gray; background-color: Gray; height: 1px; width: 100%; margin-top: 3pt; margin-bottom: 3pt" />
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt; width: 33%"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20220127__20220127_zxa24J0PcBx"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="text-align: center; padding-left: 10pt; width: 33%"><span id="xdx_907_edei--EntityFileNumber_c20220127__20220127_zm60Iqt4Kskc"><b><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityFileNumber">001-33307</ix:nonNumeric></b></span></td>
    <td style="text-align: center; width: 33%"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220127__20220127_zo58XePN3Nm4"><b><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityTaxIdentificationNumber">13-3326724</ix:nonNumeric></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; padding-left: 10pt">(State or other jurisdiction<br />

of incorporation)</td>
    <td style="text-align: center; padding-left: 10pt">(Commission File Number)</td>
    <td style="text-align: center">(IRS
Employer Identification Number)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.9pt; text-indent: -16.75pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220127__20220127_zvOAzuyFPJGk"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityAddressAddressLine1">1510 Cotner Avenue</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220127__20220127_zGRKOOm6XhRa"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20220127__20220127_zeYgBjxDExc8"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="width: 51%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20220127__20220127_zGOXoJWK3rd7"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:EntityAddressPostalZipCode">90025</ix:nonNumeric></span></b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(<span id="xdx_904_edei--CityAreaCode_c20220127__20220127_zZd97jl4AFl7"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20220127__20220127_zELO7xlfIaN5"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:LocalPhoneNumber">478-7808</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Registrant&#8217;s Telephone Number, Including Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20220127__20220127_zSXf6TgqqaHi"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_90C_edei--SolicitingMaterial_c20220127__20220127_zfTnjsHSDPJl"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementTenderOffer_c20220127__20220127_zEV37V2CJDEb"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.7pt"></td><td style="width: 21.5pt"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20220127__20220127_z5pCcx54zzjj"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Title of Each Class</span></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Trading Symbol(s)</span></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Name of each exchange on which registered</span></span></td></tr>
<tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20220127__20220127_zwUcztg79Zu1"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:Security12bTitle">Common Stock, $.0001 par value</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20220127__20220127_zsnokrqOX1Kk"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" name="dei:TradingSymbol">RDNT</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--SecurityExchangeName_c20220127__20220127_zED0mX0bAQIi"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company&#160;&#160;&#160;</span><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20220127__20220127_zTfRQ0MAhOJ2"><ix:nonNumeric contextRef="From2022-01-27to2022-01-27" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;
</span><span style="font-family: Wingdings">&#168;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 8.01</td><td>Other Events.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 27, 2022 RadNet, Inc. (&#8220;RadNet&#8221;)
held a public conference call regarding the recently Announced Acquisitions of Aidence and Quantib and its Artificial Intelligence Strategy.
Corporate participants, Howard Berger, M.D., RadNet&#8217;s Chairman and Chief Executive Officer, Dr. Greg Sorensen, CEO and Co-Founder
of DeepHealth and President of RadNet&#8217;s AI efforts, Mark-Jan Harte, Co-Founder and CEO of Aidence, and Arthur Post Uiterweer, CEO
of Quantib hosted the call and discussed the potential impact for artificial intelligence on preventive health and cancer screening. Also,
discussed in detail were main categories of opportunities in clinical enhancements, business operations, and revenue enhancements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in Item 8.01
of this Current Report, included in Exhibit 99.1 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in Item 8.01 of this
Current Report, including Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed
with the Commission.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS AND EXHIBITS.</b></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 15%"><span style="text-decoration: underline">Exhibit Number</span></td>
  <td style="width: 85%"><span style="text-decoration: underline">Description of Exhibit</span></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>99.1</td>
  <td><a href="radnet_ex9901.htm"><span style="font-weight: normal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transcript of Conference Call </span></span></a></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>

<tr style="vertical-align: top; text-align: left">
  <td>104</td>
  <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: normal">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt">Date:&#160;&#160;January 28, 2022</td>
    <td style="text-align: left; width: 50%; font-size: 10pt"><b>RADNET, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">By: <span style="text-decoration: underline">/s/ Mark D. Stolper</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Name: Mark D. Stolper<br />
    Title: Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></td></tr>
  </table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LdpNBbdLh4o4ZYwh3hYXpbg1I61/j+Rb2m2IIRCSc74cIUZiQ2tdI8NpWWRQYtPWyiEUeEFGc0bvSLe7BPws8KqtY2Vcv/7AlDyDnpmPY+XvvfOhLVYJyMVExpMoBDlL5BTyvQg6PSVz0RUap1UNylSQM7Ws0Sl+Dx9K9SJDzbtPOiJbTSaBcCwH+QORDCM40EM9iW8WsiwVwaivQGyY7m0Xc7eOGljV2PgsO6D/Dr7iWkkg -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>radnet_ex9901.htm
<DESCRIPTION>TRANSCRIPT OF CONFERENCE CALL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O R P O R A T E P A R T I
C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper, </B><I>Executive Vice President
and Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger, </B><I>Co-Founder, Chairman,
President and Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gregory Sorensen, </B><I>Co-Founder and
Chief Executive Officer, DeepHealth, and President AI Division, RadNet. Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark-Jan Harte, </B><I>Co-Founder and Chief
Executive Officer, Aidence B.V.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Arthur Post Uiterweer, </B><I>Chief Executive
Officer, Quantib B.V.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E C A L L
P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut, </B><I>Jefferies &amp; Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sarah James, </B><I>Barclays</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal, </B><I>Sidoti &amp; Co., LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good day, everyone, and welcome to today&rsquo;s
call to discuss RadNet&rsquo;s recently announced acquisitions of Aidence and Quantib, and RadNet&rsquo;s strategy for artificial intelligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a reminder, today&rsquo;s conference is being
recorded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At this time, I&rsquo;d like to turn the call
over to Mr. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Good morning, ladies and gentlemen,
and thank you for joining us today to discuss our recently announced artificial intelligence acquisitions and our AI strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participants in today&rsquo;s call include Dr.
Howard Berger, RadNet&rsquo;s Chairman and Chief Executive Officer, Dr. Greg Sorensen, CEO and Co-Founder of DeepHealth and President
of RadNet&rsquo;s AI efforts, Mark-Jan Harte, Co-Founder and CEO of Aidence, and Arthur Post Uiterweer, CEO of Quantib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we begin, we&rsquo;d like to remind everyone
of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. Today&rsquo;s prepared remarks and discussion
contain forward-looking statements within the meaning of the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business,
future plans and strategies, projections and anticipated future conditions, events and trends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements in this discussion
include, among others, statements or inferences we make regarding: whether Quantib&rsquo;s and Aidence&rsquo;s existing or any future
products will receive European CE and U.S. FDA 510(k) clearance or other regulatory clearance and/or approval necessary for commercialization;
whether Aidence&rsquo;s and Quantib&rsquo;s existing and any future solutions will prove effective and whether RadNet&rsquo;s development
and deployment of AI solutions will prove effective for improving the care and health of patients; expected market acceptance for Aidence&rsquo;s
and Quantib&rsquo;s products and the willingness of customers to use or continue to use Aidence and Quantib products in the future; Aidence&rsquo;s,
Quantib&rsquo;s and RadNet&rsquo;s ability to develop, maintain and increase their market positions in a competitive environment; and
economic benefits and cost savings anticipated to be derived from AI products and solutions, as well as the anticipated importance of
and impact of AI solutions to RadNet&rsquo;s future business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to
differ materially from those indicated or implied in the forward-looking statements include those factors identified in the Annual Report
on Form 10-K, Quarterly Report on Form on 10-Q, and other reports that RadNet, Inc. files from time to time with the Securities and Exchange
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any forward-looking statement contained in this
press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that we make from time to time, whether as a result of change
of circumstances, new information, future developments, or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I&rsquo;d like to turn the call over
to Dr. Berger, who will make some opening remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark, and welcome, everyone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today, I would like to describe to you not only
the rational behind the recent announcement, Monday this week, in the acquisition of two additional artificial intelligence companies,
but also expand on what the potential overarching opportunities are for this investment. Monday&rsquo;s announcement marks a seminal event
for RadNet, and perhaps imaging, but not limited to just the specialty of radiology imaging, but perhaps also for the healthcare market.
Artificial intelligence has been a term that has been used for quite some period of time and it has yet to develop a coherent strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today&rsquo;s conference call is an attempt to
explain some of the factors which led RadNet to make this investment, and my remarks will focused on three themes that I would like to
expand on: number one, consolidation of artificial intelligence around cancer screening; number two, technological advances in equipment;
and, number three, response to the needs for these tools heightened by the recent pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let me start with the first, and perhaps the most
important. When RadNet first made is entrance into the artificial intelligence world almost two years ago with its acquisition of DeepHealth
and the leadership of Dr. Gregory Sorensen, who heads that division, we have, for the last several quarters, been talking about expanding
screening tools for cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our first entrance into this market was out of
our own needs internally for RadNet, given the fact that RadNet does almost 1.6 million mammograms a year, which represents about 4% of
the entire U.S. market, and which we felt was a good investment that would improve both diagnostic accuracy, as well as earlier detection
of breast cancer. Since that time, we have been diligently searching for other partners whose products and whose strategy would complement
that of DeepHealth and breast cancer screening. We were fortunate to find two such companies, both in the Netherlands, which have been
doing artificial intelligence work, primarily around Quantib&rsquo;s efforts in prostate cancer and Aidence&rsquo;s efforts primarily
in lung cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;m pleased to report that after our own
extensive due diligence, we believe that combining these two best-of-breed companies for these two cancer screening tools, along with
DeepHealth in breast cancer, gives us the platform to start a more focused strategy on cancer screening not just as a diagnostic tool,
but for population health, much similar to what has already been established for the use of mammography in breast cancer and which is
now something that women do on an annual or biannual basis as part of their routine health and wellness. (Audio interference) efforts
in the way of prostate and lung cancer are here today and need to be availed. With what we will do internally with these three outstanding
teams, meaning DeepHealth, Quantib and Aidence, is internally develop our own colon cancer AI screening tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Putting the four of those cancers together, we
believe that the screening for almost 70% of all cancers&mdash;solid tumor cancers, that is&mdash;can be detectable earlier with not only
artificial intelligence, but new technological advances in equipment. We believe that the opportunity for this is not limited to RadNet,
but limited to payors, health systems and to governmental agencies that formulate public health policy, and that all of these at some
point in time should be tools that, much like mammography for breast cancer, can be accessed directly and routinely by the general public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second tenet that I believe is important here
is that this is only possible because of additional advances that have occurred, principally, in the last five years, on the equipment
side. In mammography, we&rsquo;ve had advances for digital imaging, as well as better resolution on detectors that allow every radiologist
to see the cancers earlier, and with CT scanning and MRI scanning, the recent advances have allowed for greater flexibility in the patient
experience by significantly shortening scanning times, primarily in MRI, which now makes the adoption of artificial intelligence and screening
tools more accessible and at a lower cost, and I can&rsquo;t emphasize enough how important that is in marrying the artificial intelligence,
which is the reading part, with the technological advances in the equipment which actually performs the scan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third, and maybe even the most important part
that I want to emphasize here, is that the response by us and the equipment is magnified by what the pandemic itself has exposed in the
way of challenges to make certain that as these tools become adopted that we can accommodate the needs of the public to provide these
invaluable tools, and I&rsquo;m particularly referring to the staffing shortages, whether it&rsquo;s on the professional side or on the
technological side, that I believe are a fact of life that we will be living for the foreseeable future. The tools that we&rsquo;re developing,
and, hopefully, that others are working on, will allow the access to equipment and the reliability of these tools to be formed with less
dependency on the staffing that traditionally has been necessary to produce these images and their reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a critical juncture for society, in general,
to make cancer screening a reality. The potential implication of the volumes and demand for these procedures will become self-evident,
and much like the impact that artificial intelligence and mammography have already begun to have on breast cancer in earlier detection,
which both reduces morbidity and mortality, will become even more obvious with the other three major cancers that RadNet will be focused
on, lung, prostate and soon to be developed, hopefully, colon cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opportunity here that lies ahead of RadNet
and the challenges that come therewith are important not for just RadNet as a company, but I believe a response, perhaps, uniquely by
a company that can merge the extensive resources that we have within our imaging centers and the data that we own to help facilitate the
development of expanding AI tools in the cancer screening market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I should add, and parenthetically acknowledge,
that the tools that we will use both for artificial intelligence and the equipment to produce the images and the procedures that we do
have other potential implications. Given the fact that the areas that we scan provide information regarding anatomical and physiological
aspects of an individual&rsquo;s health and wellbeing, the implications for using cancer screening as a tool to look at other potential
diseases, such as diabetes, cardiovascular, and other more chronic diseases, should not be overlooked. That information is on the scans
that we produce and it generally in the past has never been accessed, but I read articles regularly about how various artificial intelligence
developers are looking at ways that all of this information can be used to help both the clinicians, the payors and governments look to
manage the health and wellbeing of their populations. So, the implications of this are extensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;re excited to welcome both the Aidence
and Quantib members to the RadNet family, and, combining that with DeepHealth, we not only are the largest artificial intelligence company
within radiology, but I think, clearly, the best with this enormous talent that we&rsquo;ve brought together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, I&rsquo;d like just to introduce you
to Dr. Sorensen and the leaders, Arthur and Mark-Jan from DeepHealth, Aidence and Quantib, to make a brief opening introduction. Hopefully,
you&rsquo;ll be hearing from them, in addition to other RadNet conferences, on a regular basis. So, Greg, perhaps if you can start with
your comment, and then turn it over, and we&rsquo;re ready for that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gregory Sorensen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fantastic. Thanks very much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d like to just expand briefly on Dr. Berger&rsquo;s
comments about why cancer screening with AI is the highest impact and most valuable area of focus for us today. It&rsquo;s just simply
our best opportunity to have the biggest impact. There&rsquo;s both a medical reason and a machine learning, or AI, reason for this, and
I&rsquo;d like to explain both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the medical front, there&rsquo;s very clear
evidence that detecting cancers early, before they spread, saves lives and reduces costs. Because cancers are almost always more treatable
at lower cost when we find them before the cancer has spread through the body, advisory bodies in the U.S. and around the world recommend
cancer screening. In the U.S., this includes a recommendation to screen for breast cancer with mammography, for lung cancer with SP scans
of the chest, and colon cancer, also with CT scans, and screening is extremely effective. In the lung, for example, the survival benefit
from screening far outweighs any survival benefit from chemotherapy, or even new immunotherapies, and it&rsquo;s much less expensive.
In short, screening is a major public health benefit and it impacts tens of billions of people in our country and in our markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the AI front, modern machine learning techniques
are very powerful at learning, but mainly at learning what they&rsquo;ve been taught; that is, what the computer&rsquo;s actually seen
examples of before. Modern AI is not as powerful at extrapolating. It best learns from examples. In screening for cancer, or imaging,
we get literally millions of examples, and so the algorithms can really learn well. We&rsquo;ve shown that in some domains the algorithm
can actually do better than human experts at certain image recognition tasks. So, put succinctly, large-scale screening is a great match
for modern AI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, when you put the medical value proposition
of screening together with the fact that machine learning is best suited for tasks with millions of examples, it just becomes very clear
that cancer screening is where our real opportunity lies, and since, of course, at RadNet, we do literally millions of screening exams
a year already, we&rsquo;re well positioned not only to develop these tools, but also to implement these tools that will have a positive
financial impact on our business, and, more importantly, a positive health impact on our patients, as we roll these technologies out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those are my opening comments. I&rsquo;d like
to now turn it over to Mark-Jan Harte from Aidence to offer his comments, and then hear from Arthur. Take it away, Mark-Jan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark-Jan Harte</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks very much, Greg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, from my side, Aidence has been focused on
the early detection of lung cancer since we founded it in 2015, and, as with many cancers, but especially lung cancer, the survival rate
increases dramatically with early detection, as Greg referred to earlier, as well. This is why the U.S. is reimbursing lung cancer screening,
and also why the NHS in the United Kingdom is at the moment running large-scale screening programs for the at-risk population, with the
intention of scaling this up to a national level. Many other countries in Europe are following the same path, because they see the same
benefits. Aidence&rsquo;s strategy is be the partner of choice for all of these programs, and, of course, partnering up with RadNet provides
us with a huge opportunity to increase our ability to do that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the treatment of lung cancer with
powerful therapies is advancing quickly, with companies like AstraZeneca, for example, obtaining approval for early-stage treatment with
their drug Tagrisso, and since it is crucial to identify the eligible patients early for that treatment, Aidence is a very attractive
partner to pharma companies that already have or are planning to bring such early-stage drugs to the market. That was illustrated very
well by the collaboration agreement that Aidence has signed with AstraZeneca in July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, with that, I would like to turn it to Arthur
Post Uiterweer from Quantib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Arthur Post Uiterweer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Mark-Jan. Let me talk a little bit
about Quantib, and thanks, everyone, for giving me some time here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantib chose to focus on MRI prostate as our
second clinical application, because of three main reasons: it&rsquo;s a high-growth procedure, there is a big time cadence potential
there, and there is big potential for quality improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The high growth is underpinned by medical associations
making MRI a standard procedure prior to every biopsy, causing a at 5x growth in this domain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reading these exams is very time-consuming, about
20 minutes per patient, while AI has the potential to reduce this to about three minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lastly, we observe a large variability in the
reading quality between radiologists, which is largely solvable with AI tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantib has created and received CE and FDA clearance
for our MRI prostate solution, with our first users seeing, indeed, enormous time savings, as well as improved consistency in performance.
We now bring this product to RadNet to further improve it, using vastly more data that we now have available. This will positively impact
the RadNet users, as well as our users outside of RadNet, and we are very pleased to be part of this big team and really boost our impact
on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for allowing me to make some comments,
and I&rsquo;ll pass it back on to Dr. Sorensen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Operator, it&rsquo;s Mark Stolper.
I think we&rsquo;re ready to begin the question-and-answer portion of today&rsquo;s call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We&rsquo;ll pause for just a moment
to allow everyone an opportunity to signal for questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ll take our first caller from Brian Tanquilut
with Jefferies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey, good morning, guys, and congratulations to
everyone. I guess just a couple of questions for me. Dr. Berger talked about the opportunity here in expanding testing for the different
hard tumor cancers. So, how are you thinking, Mark, or maybe Dr. Berger, in terms of commercialising this, right? I mean, what are those
conversations like with the payors and how are they thinking about driving increased screening among their patient populations using the
tools that you&rsquo;re offering them?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Brian. It&rsquo;s Howard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think the conversations that have already begun
will certainly get amplified as a result of the announcements this week. I believe at every level, whether it&rsquo;s payors who we&rsquo;re
already talking about these tools, or even governments that have a national health program who we&rsquo;ve already begun discussions,
or discussions and relationships are already in place with both Aidence and Quantib, I think that the opportunity is obviously not just
nationally, as RadNet has been focused since its inception, but also on an international and a global basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of what needs to be understood and adopted
is to create these cancer screening tools that become part of public health policy, much as it has already begun, as Mark-Jan pointed
out, in the U.S. with lung cancer screening, and as has begun and talks are ratcheting up, in many of the European countries, I do want
to point out that even though lung cancer screening in the U.S. has been approved for reimbursement, only perhaps 10% of the people who
buy risk assessment qualify for lung CT screening are currently accessing the opportunity here. Part of the problem is that it hasn&rsquo;t,
as yet, been made easy enough for people to access this without going through substantial referrals for the procedure, as well as authorization.
In order to make these tools more effective and universal, health plans and governments are going to have to make it a part of their health
plan policies and adopt this into their reimbursement or their coverage, much as they have with mammography or breast cancer screening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, that&rsquo;s the challenge that&rsquo;s in
front of not just RadNet, but the marketplace as a whole, and how do not only adopt these tools, but then improve compliance, so that
people understand the value that this can play. Hopefully, what we&rsquo;ll be able to do is develop other tools, along with the screening
that might give information, as I alluded to earlier, about other aspects of a patient&rsquo;s wellbeing, and earlier detection of non-cancer
diseases, as well as how do you evolve the plan design to help encourage the compliance. Part of that problem, again, is demonstrated
by mammography, which is estimated that only 50%, or slightly more, of all the women who qualify for mammography are getting it on an
annual or biannual basis. So, part of what we&rsquo;ll be talking about with health plans and governments is how do we get the compliance
where these tools that are potential lifesaving are better understood and utilized by the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the attractions for the Quantib and Aidence
acquisitions was that they are rooted, obviously, in Europe, specifically, the Netherlands, and most of the European countries have a
national healthcare program. So, to the extent that we can speak directly with the public health officials and the leadership in the healthcare
systems in Europe, and they adopt these programs, we&rsquo;re essentially bringing in 85% to 90% of the population under these kind of
opportunities. That, indeed, in and of itself, represents a far different opportunity than here in the United States, where the Medicare
or CMS covers maybe 20% of the population and we have to speak individually with all of the other commercial payors in order for each
of them to adopt this.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There will be a multi-pronged attack on these
efforts, which both Aidence and Quantib have already established significant commercialization opportunities that will not only facilitate
further discussion as we add mammography, and eventually colon cancer screening, to our tools for Europe, but also as we further adopt
these and implement it into our centers and other centers across the country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I want to point out that it&rsquo;s important
to remember that RadNet has extensive joint ventures with some of the largest healthcare systems in the country and the adoption of these
tools will be greatly facilitated by those relationships that we have, not only for the centers which are part of our joint ventures,
but all of these systems have other hospitals that RadNet currently doesn&rsquo;t have more specific relationships with. So, putting all
of these tools together, and a full-court press, if you will, is a commitment that RadNet is making to rolling these out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No, that makes a lot of sense, and I guess my
follow-up, Mark, as I think about the capital requirements for these businesses going forward, any color you can share with us on that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mark Stolper</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, Brian. DeepHealth, as you&rsquo;re probably
aware, is running at a loss. In 2020 and 2021, those are losses are embedded in the financial results that we&rsquo;ve been reporting
each quarter. The acquisitions of Aidence and Quantib will increase that loss, and when we issue our guidance in or about March 1, when
we report our year end 2021 results, we&rsquo;ll give you some more transparency as to what those losses will be like. We&rsquo;re having
some discussions internally and with our auditors about further disclosures that we&rsquo;ll be able to make on a quarterly basis, that
will essentially separate the core imaging business from the financials of the AI Division, inclusive of DeepHealth, Aidence and Quantib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">But, for your own kind of thoughts right now,
DeepHealth has been running around a $4 million to $5 million loss. We expect that to continue and be embedded in our financials. I would
expect that Quantib and Aidence will add to that loss in the $10 million to $12 million range, and that&rsquo;s reflective of further
investments that we&rsquo;re going to be making in those companies, in personnel, especially, to try to accelerate both the commercialization
of new products, the further development of those products, as well as increasing the Commercial and Sales Teams of those organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, we&rsquo;ll have a lot more to talk about
it financially in several weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Brian Tanquilut</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awesome. Thank you, guys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. Next, we&rsquo;ll move on to Sarah
James with Barclays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sarah James</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, and congratulations. This is a very
exciting strategic move on a lot of different levels. Just to follow up on the last question, as we think about it today, are these two
new properties going to be revenue accretive for you, and then should they get approval in the U.S., how do you think about that revenue
model working for selling externally or the efficiencies that they could offer you internally? I know you&rsquo;ve talked about mammography,
saving about 25% efficiencies, but I&rsquo;m not sure how these compare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, and thank you, Sarah, for joining
us&mdash;I&rsquo;m sorry, Rebecca. The opportunities here for the commercialization will eventually over&mdash;or dominate the opportunity
for RadNet from a revenue standpoint. The importance on the time savings, or the benefit for our radiologists is really twofold. One is
not only to reduce the amount of time that it would take to read these scans, but also improving the accuracy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think, as Dr. Sorensen indicated here, all of
these tools should be capable of diagnosing cancer earlier. Now, by that, I mean it&rsquo;s not that the radiologists are inadequate,
but, from an intuitive standpoint, cancer, which, theoretically, starts with one abnormal cell, then proliferating, should be detectable,
from a programming and artificial standpoint, much earlier than the best of radiologists. The ability that we have currently in mammography
to separate highly suspicious from non-suspicious mammograms, that has already led to about a 20% improvement in productivity. When it
comes to prostate and lung cancer, the tools that we&rsquo;re talking about will reduce the amount of time that a radiologist typically
spends circling lesions, identifying them, determining size and density, and automate this process, which could reduce their workload
by perhaps 50%, or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The backdrop of all of that is that the current
shortage of radiologists qualified for these highly specialized tools will allow the current Radiologist Team to read these scans faster
and more accurately, and ultimately produce benefit to RadNet from an operational standpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, I think your question is well designed, in
that eventually, we hope within a couple of years, the AI Division will actually become cash flow neutral for us, as we expand to markets
well beyond RadNet centers, and during this interval we will get significant improvement, from an operational standpoint, on the efficiency
with which both our centers are capable of doing the exams, as well as our radiologists in improving their reading and their accuracy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sarah James</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, and can you give us any guidance on what
the FDA approval process looks like, what a reasonable timeframe would be for you guys to hear back on that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg, why don&rsquo;t you respond to that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gregory Sorensen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sure, I&rsquo;d be happy to. Thanks for the question.
Both Aidence and DeepHealth have made submissions to the FDA in the last month or two. The FDA, typically, has its own internal 90-day
clock, that under MDUFA, they promise to, essentially, get you an answer within&mdash;or an answer to 95% of the companies within 90 days.
But, of course, that clock can stop, and it usually does, during kind of a month or too long Q&amp;A period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think, realistically, we can&rsquo;t expect
the FDA to do anything this quarter, but I would say that, probably, in the next two quarters, it would be highly likely that we&rsquo;ll
not only have substantive engagement with the agency, but&mdash;and, of course, this is modulated by the COVID slowdown that so many groups
in bureaucracy have been forced to deal with, but assuming that that doesn&rsquo;t get worse, I think some time in Q2 or Q3 is when we
expect to see approval of these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sarah James</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And last question how does Quantib and these prostate
products work with what you were already developing into the prostate market?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Inaudible)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gregory Sorensen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think you&rsquo;re referencing&mdash;or go ahead,
go ahead, Howard. You might probably (inaudible), but happy to follow up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You do it, and I&rsquo;ll expand if necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gregory Sorensen</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. When DeepHealth first became part of the
RadNet family, we already had the vision that prostate would be an area of interest for us. As we described in the press release and as
Dr. Berger pointed out in the initial part of the call, although prostate cancer does not have a screening paradigm with imaging, the
way these other modalities do, there&rsquo;s&mdash;as Arthur said, there&rsquo;s very good evidence that if you&rsquo;ve got cancer, or
suspected to have cancer, or for some other reason you&rsquo;re going to undergo biopsy, imaging is playing a critical role, and we think
it&rsquo;s a matter of science continuing to develop, that eventually there will be a role in certain high-risk populations for prostate
cancer screening. That&rsquo;s why two years ago, we already knew prostate was important.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What we get with Quantib is someone who&rsquo;s
been working on this for more than five years and already has a big customer base and a lot of experience. It, essentially, let&rsquo;s
us leapfrog the efforts we were going to do, and that was part of the attraction for us for acquiring this company and their team, very
talented team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maybe if I just amplify a little bit on this,
Greg. Once we acquired DeepHealth and its mammography AI tools, the decision to expand into other significant cancers, namely, prostate,
lung and colon, became a matter of buy or build, if you will, and the decision at that time, since we weren&rsquo;t at all invested in
prostate or lung tools, was to look for a good acquisition opportunity, or opportunities in this case, rather than build it internally
ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The turnaround time for developing a product and
submitting it for approval to the FDA or CE Mark in Europe is probably close to two years, between all the testing that you do before
you submit to the governmental agencies and then the time that they take to finally give you approval. So, we felt that the urgency for
us to take advantage of the platform that we established with DeepHealth, and rather than invest the capital to build these, to find best-of-breed
in at least two of the other categories of cancer related to prostate and lung was a better way for us to invest our money and time, to
buy rather than build.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fourth leg of this stool for colon is something
at this time that we have not found anybody else doing with the type of screening tools that we think are capable today with both AI,
as well as technology or equipment, and so that one, we&rsquo;re beginning to develop a strategy, develop ourselves. Really, the leap
into the acquisitions did not augment any development that we had internally for cancers, other than what we were already deeply involved
with, breast cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sarah James</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, that makes a lot of sense. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next, we&rsquo;ll take a question from Mitra Ramgopal
with Sidoti.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, hi, good morning, and thanks for taking the
questions, just a couple for me. I was just curious if you could provide a little more color on the acquisitions themselves, in terms
of how the process was initiated and sort of how these two companies showed up on your radar, given that they&rsquo;re both outside of
the U.S. Historically, your acquisitions tended to be domestic. Also, aside from expanding the AI platform, was there a determination
you also wanted to expand your geographical presence?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good morning, Mitra. Thank you. The world of artificial
intelligence and the players inside of that is rather small, even on a global basis. Both of these companies have been around for seven
to ten years, and so they were fairly well known in the industry as to their efforts in both of these cancer initiatives. So, as we screened
the available market for acquisition opportunities, they quickly popped up on our radar. Then, along with our physician advisors internally,
they helped us look at their current products and give, so to speak, a green light as to the quality of these. I&rsquo;m happy that in
both cases our physician advisors were very enthusiastic about not only the quality of these tools from a diagnostic standpoint, but from
the relative ease of operation that will allow them greater efficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The universe of people out there is relatively
small. We began the process, probably, about seven months ago, back in maybe the summer, around the August timeframe, where we met with
the companies and began discussions about acquiring them. Both of the companies, as you may know, were venture capital backed, so that,
along with the fact that they are domiciled in the Netherlands, where both the financial, as well as legal structure can be substantially
different than here in the U.S., made it a bit more of a challenge, but the challenge was actually beneficial to the Company, because
we got to know the individuals more carefully, and I&rsquo;m happy, and perhaps most pleased, to report that the cultural fit with these
organizations, both as demonstrated by their leadership, with Mark and Arthur, as well as their Chief Technology Officers and Development
Teams and Commercial Teams, are at the highest levels that we had seen. So, for us, it was an easy decision to make, but a little bit
more difficult to execute. So, that&rsquo;s the breadth of that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What was the second part of your question, Mitra?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, Howard, the geographic presence, expanding
outside of the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think the geographic opportunities really
will help to further commercialize not only our artificial intelligence initiatives, but also our eRAD information technology tool. We
plan on integrating these tools to be far more effective together than either is on a standalone basis, and we think that that will be
a substantial offering and attraction not only outside of the U.S., but inside the U.S. where RadNet doesn&rsquo;t own centers. So, this
opportunity, ultimately, will be what we call capital-light, in the sense that it will not be heavily investing in equipment, but looking
at ways that we, essentially, will transform a part of our business to be a tech company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of what Mark has talked about in terms of
reporting the results of AI separately from the operations, and other opportunities that we have to heighten the potential value opportunity
of artificial intelligence and IT platforms, will become a little bit more evident, but we do plan on expanding anywhere where these tools
can provide benefit to the population, whether it&rsquo;s internationally or nationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mitra Ramgopal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, thanks for taking the questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. We have no further questions at this
time. I&rsquo;d like to turn the call back over to your presenters today for any additional or closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Howard Berger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, Operator, and thank you all for joining
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a very important and potentially game-changing
opportunity here for everybody, and I think we are making a very bold statement as to where RadNet can contribute not only, as Mark mentioned,
to our current stakeholders, but stakeholders anywhere that want to try to provide better health and better outcomes for its population.
Expect more to come from us as we evolve this opportunity, but recognize that RadNet, not just as a company, but as a societal opportunity,
is committed to better health, and as I have said in previous conference calls, good medicine is good business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With that, we&rsquo;ll look forward to our fourth
quarter earnings call in early March and further updating you on our opportunities. Thank you all and stay safe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. That does conclude today&rsquo;s teleconference.
We do appreciate your participation. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rdnt-20220127.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaKOKaPty552CYkxvmR7fQkqzywvPfs/XihJKrD2cR8O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:RDNT="http://radnet.com/20220127" elementFormDefault="qualified" targetNamespace="http://radnet.com/20220127">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://radnet.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20220127_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="rdnt-20220127_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rdnt-20220127_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rdnt-20220127_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.11a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://radnet.com/role/Cover" xlink:href="rdnt-20220127.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://radnet.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139886340788312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 27,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RadNet, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000790526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3326724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1510 Cotner Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-7808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RDNT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>radnet_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdnt-20220127.xsd" xlink:type="simple"/>
    <context id="From2022-01-27to2022-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000790526</identifier>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-27to2022-01-27">0000790526</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-27to2022-01-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-01-27to2022-01-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-27to2022-01-27">2022-01-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-01-27to2022-01-27">RadNet, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-27to2022-01-27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-01-27to2022-01-27">001-33307</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-27to2022-01-27">13-3326724</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-27to2022-01-27">1510 Cotner Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-27to2022-01-27">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-27to2022-01-27">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-27to2022-01-27">90025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-27to2022-01-27">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-27to2022-01-27">478-7808</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-01-27to2022-01-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-01-27to2022-01-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-01-27to2022-01-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-01-27to2022-01-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-01-27to2022-01-27">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-27to2022-01-27">RDNT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-27to2022-01-27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-27to2022-01-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "ES/%0'04UB@0   +$    0
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M:0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  I<SQ4EXJ[',     3 @
M"P              @ %%#P  7W)E;',O+G)E;'-02P$"% ,4    "  I<SQ4
MJL0B%C,!   B @  #P              @ $N$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ *7,\5"0>FZ*M    ^ $  !H              ( !CA$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *7,\5&60
M>9(9 0  SP,  !,              ( !<Q(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  O1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="radnet_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://radnet.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="radnet_8k.htm">radnet_8k.htm</File>
    <File>radnet_ex9901.htm</File>
    <File>rdnt-20220127.xsd</File>
    <File>rdnt-20220127_lab.xml</File>
    <File>rdnt-20220127_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "radnet_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "radnet_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rdnt-20220127_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdnt-20220127_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rdnt-20220127.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "RDNT",
   "nsuri": "http://radnet.com/20220127",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_8k.htm",
      "contextRef": "From2022-01-27to2022-01-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://radnet.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "radnet_8k.htm",
      "contextRef": "From2022-01-27to2022-01-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://radnet.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001683168-22-000553-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-22-000553-xbrl.zip
M4$L#!!0    ( "ES/%0!4*G1\A,  "I_   -    <F%D;F5T7SAK+FAT;>T]
M:U?BRK+?7<O_T)=SYRQG;8$$4!XZG(6 #CX @1F=^>+J) U$0Y))@L#\^EO5
M22"!H*#XN/?BWJ.2=%=55]>['Q[_9SS0R".S;-70O\7$A! C3)<-1=5[WV)#
MIQO/Q?Y3W-TY[CO0#MKJ]K=8WW',0C(Y&HT2HW3"L'I),9_/)\?8)N8V*HPC
MVZ4$04S>7EVVY3X;T+BJVP[593;MI*GZPW+X^';:5+(T-=04G_A(TLD%T/!6
MF74(-CY,NB]#39W(I@=N4\=OJMI&)B5FGZ+#;3'M,%[65D2:883L]J1U.6ON
M1+>?-4TZ%M7MKF$-J -SB) .XD(JGCH, (G;3 X!@L^)GO'X+)Q</"WZ<!8F
M)SQ2?"U1>\IQA<VQV\<)+Z!'2OR3\9M:K+L4\&$2WOH-AW:\1ZDY;=REML0;
M>B\XW+@@!JB&-Y:A,3NR#W\3T4DVAKIC3:+I]U[R;GX'VW(6$<##"-BM2KTS
M;6M116=.0C8&V!)XGLK&N+HQJL!/@E_'CNIHK'B<='_"VP%S*$$(<?9GJ#Y^
MBY4-W6&Z$^],3."_['[Z%G/8V$FZ6IG$?DD/[/%_Q>/D5&6:4B!MYAR1.AVP
M ADKXR-2J_!?[H14Z>Y'^TNJ<E8J->$'#H3$XZOV3N?N<*!WLP'>^0-< THF
M->WUDNX'Y3L&T@;4P_]5'?@W*0-C+*K5=(6-+]CD3H"O;%XX2!VN S<?@%L:
M,%V!?\ZI1GMW7:K9; U0AR? Y<J=>.<9"A<F/%H'1NJNW:<6L^]2=]PNND!L
M_FP=.!6DI>G!2B^0M!2X9"@38CL3C7V+=4'X"D043(=TU $TJ;,1:1D#JN^[
M#_:! $OM<C%7U$>_GZ+:ID8G!:(;.N,OU7$!Y959J C\DZHH3.=J@1^A87TX
M %BR*_%CIX5VY-0R!B@KJ'6IK&/,?H\1'48-J)A:B)2&6'$F#L?)$(K78'6-
MZK<8&.*"9(#)H3H7DR ](2F*%?G[2!*2(48@16 ?F05.F]EN"S3$!9M[6""-
M<+=9Z',;:RE@)'Q%2HQM)>:]=L!P?(O9ZL#4F&LL/%1AX"XZVQA:/C9HQJ6B
MX#&#J,J3S/"-FM^-\7F8/IT^5Q5\TU691?A06*3[*M<NPG,VWWF&+AF)S\-F
M G\-99$*B"$LIT(=5IP-P8<T>[?0#:9R22?_S3Q9(0+\AQY+PWP>ZJK+9%#(
M!6X.&+6'%BMZFEN -CXP_U48!4); M\U TM1>$S@C5Z,8V9N%O" :8!I7.0M
M]N4*01W#"KQ>GP?S-$9!#2"M,-T8J/IS:)_GRSS>*,#^^Q 7%ACJ:6A 'UWS
MX%O-XR3TAY_XW[&YKH4^(@-J]52]0+"I$(,(Q"Q&@9(,35D#7MPQ3 YS^D R
M',<8>,]0Y.-44WN 6 9U95:L^*->ZU0KI-TI=:KM962\*07'4K%=+?]HU3JU
M:IN4ZA52O2U_+]7/JKL[Y<;55:W=KC7JQTGI [ET0^T^Y&V. 2 KB7*"I(2#
M3/XU[%K$LA)YG%W__I=X*!P]Q9&WI<!'&HA\6D.-Q9NTQP.T8/#A"WH:"*)#
MQS@B(U5Q^@62.O@2"[64# MTR\5]HE'Y@8C0QS8T53DB.*RXK?Z%R$I$&GP6
MH!9ZWP/4)$/DO#N#?.(^0IELD^I!?#[3,I[LG#9:5T 3;X9^ L/3O)#F47<\
M7C'D(89*F.W<R=,$898J_+5LJ^TP^V>M]P#P7ALK!O'%BKGXQ7Q@=IQ$2HNN
MK'N_?H#(OWY&M]KV>>?F-:X+'%>K6N^05K79:'5>:Y-?0TES:-E#JCO$,0"<
MC*6FW1TQ30R+B =[RE=B=(G39_AN:*F."G14QW*?ZC!O)=G!UV(^G?DXM_+Q
MCFU3%+QX&C&#P8EH,=.P'++G?=[=813"4V8[A#U"4V+Q]TR!0'7.DI_.6?(F
M3W^J;G(4;=(=\;I%=<N4#E,O-NG!1%P!3 /HUU?H9 *$,SW*Y(<(BQ7/J3ZD
MUH2DLOL$ 2]Q!%\_9%KNUOOZC"XJ][;&9UX,JYX8NL6@%NNI-E;!'2R.14NA
M_7!=;?2;74OL;2"PB,(;*[:H4F?./JGI<N+)2.,#9&RO.J9@A7$(: &L*>F[
M.]0FMLED++LH1 4V.S8!PPT&P-J /DR3T#D)ZEMSL8(72@A',!^:817(F44G
M1T2"X*%G&4-=B8>>]YG:ZR,EYG@:AHB"\"7,HW0$C^"95U;?^* <*FD,>*YI
M)E7<I3@AQC_#[,O^9W? _->U\2\=Z5+-1;*FO'YDEJ/*5//% [KZ!9QC1_%;
M15D);T!QC74]4J?$I--?(K6T%-)2T K# K_"5ZG:#ICELKL>4S:4)4H[IJG,
MN="43\:;\!RXEH;%/X>9EO&(FA!V'2N0"2Z4:70$3N=)_7:4#?%TCJ'9$$-/
M58T!>HE9T=P;' JU/T[FPGZ0W>G9C-6;H<4*KAA/I]-"=I$=@8QJ578\-?3#
MT- [=%SS2L4RGZBG^& <Y&Y9LYZN#S*;Y,,2&F)%,0T\21UF4YGGN +?K+?3
M3S#Z7'XQ1#<@-+?(/43FMJ+RX/U8LK@1W-T!=Z &A?[K:P08D):-P4"U<5\"
M05DA+E]6A@H0:JWV[DYU8&K&!*@.<SD$SF=@DAO>315,^?=#(9&?.E-51QH*
M)"X>)K('FTP+7XYRYFN"OF7>]T34:H)F!OV(*V!K"Z$'(9/_,GWY6BZ\,/XK
M*8K%;-O[<:GJ3(RV!(^-TM_AY+1Y?K:)ZM)2Y& "#D2!E U'!_$M04HU?-I?
MF._.P%04 \OP:\/J&",]FGUGK8M&8W!XVV_13;-OACI6O#1L4M)[3,-UF$BN
M[2_DI9'CX=:O837!VX.!6Q)CL%^]D_MQI3J6<YL>U!S^6+%<>D8,HFVDIVD'
MXCMHVGR%XGW%LAPUC4T#@C;MMVHN#Q3/&K?&^<U%VE*RFY[$$/98,2\(J8-5
M9M%S32\PK NV>JU*O.N#/>(QU3,M$#[5I!IA8R8/'?41,T!PI\S^^F2(M@DZ
M@&\$&?<U(NS!9="9W_Y,U8RW1+TW+_,93^;1!)8L1I=+^6\EG[W7,J53;1-2
M'L07*Z9%85E-;,'8YCV*+PV0Y6;?T)],0ZJ7C>Q8Z]9H_6 #5,_CC!4SV5P\
MFQ-R2Y7R(R9Y5AKZ][]R*3%[9),..#03"?<B6%XGTH88J1&<!U]//E]Q;TW4
MF PL1VRY91LAFI)RG\D/?!V!FI"E@^W"!$8RQD1BFC$BJKO(< I9/<G%+TA7
MU8!_NSNJ#3F,PR!F5G"!PE8'0\VA.C.&MC8A-F0.=G?"N[H]B"$!L6Y"X2U<
MS$IB9 AP+$+UB?^N:VB '?MAZ4#%W,8NO%UM;+4RTCO4CI[W71%A2B+K+BRB
MI5]XFQ(3/)E9]!M=.E"U28'<P/APS/9B$< W/#>6ZL!D8Z(YU+V\T(ZV/NW;
M[F&G]^</_:YN9/5AV3; 2)+<B<T=+35- 9\(_SP80%<0"#$#*V^X%DHRJ0-/
M1.<6W'"=;4_,DO)IBZ320@(:!O+DUWK;K<R^1&;]D+9M:*H,TZ3WKL"D@5W3
MH@6VV]'O[>_M2O-<>U.!7:1G36F= 8!I<"$LBJJ8H7$Q%9#6T)KP5%8S0L)M
MN177#Q97?ZM.TV)HRW #,=]!@Z[5:G2[2Z.\G^GLSU3YO%*5WE1LE].UIO@"
MH+@<@/2LU14S2CRU)WU=39C=MEMQ_F!Q%J+%N6;;0V8]*]0'9ED>'V3^_KV_
M?T^A7J#NS44[S>*9/7DUT?;:OIMHO\<J.:8LL6(@DG*3 69!.F%&;GSBEL#+
M#H!%&T@&7K"H_]H5@1<8 6^Q7H:$B)HV*Q#_-V^A>;&,-&\&W%&%=P$N&6'4
MDN#:IY5"W3@.A<G>4E?!E7@\2ADK=O"4'LYIE<I]4M:H;4<HV+/C@VE<<W"9
M]QB<17FEH3T92(:V%RC]K3&T3SMU=6];"\.98[[I@MQ^U%?AR4R;HRSF=!%V
MHPQXY: 7ZX.>=9J(*8E+:K3+&OV0_SJ];/[W4-Q M6T>9ZR(?@KXVG8,^6&?
M_'="$ 21F-0BCU1[8I7K#?1G8PSV8P1/15P-6;*+3#<>K#^-6_%B$PN((82Q
M(AZ[W00#/T)(RW-"ZH</RS?D52O"X%:02M>UC11F^.8>U/S%?3U1-(')*+4K
MI6MRIAD2)*Y7U'I@SBKQU?R.@T\4\$P!UG0%@SU&I F1>445&CR ,61\&\A<
MM5.U"<PE1(H(H[>[T[.,D=/'H-'$$BBUB<*Z8&;YYD"W "4<1&SWGNWR3I,]
M'%/VB!>A_,8JWU9HXK9"W)+B1IXI*9Y:A+6[$[5W? H5P]!9QP#<Q,:8&-86
M7K1^*@5Y1EVJ2YCKSGSPNR]K+TEV*J'54Q_G&<=8=A%&ZV*GV[H6KDK]QOEF
MMF@ORW.>(&S5%.>M2NX;.&3Y4N&H=7=W @I(PB*R#UH7J<WJPK)%'U25:9"B
M@*KJ!D]8AC;CK6 &O<41O"Q$Y>L>[M%EG+C='42F31#[2 7<J/<ZT MJ:K%'
MU8:.8 &H+F.1C\K\(@ULC%>U*-12;'==1(E.ER"_W*/3;"FHV0EW%M">KB[V
MOJ"$).)SRL33 -<\6+J%NGB@.7!.#$^('4'[/T.L>\!TN<?%>+"T>#+-SZT7
M#J<%D_'#B&3\T*URK5-O6YHSS^76"]LGGBZF194P%LMG//_R9R&RP ;YYY+8
M,'3WB,O7(X*'*0ND9%%)E?WK2)#W=>.(-$Q>82J0[_RB"YP!#W7P0)\/BQ\O
M7$)3^DND!PX.)%AZ\@_,+\RVQ>A#7&)@Y(!,DXO(:C,\E=2 Z 7%.80Q.+JG
M3BIN2(M>4.U=&?/[E'R%I>5>4=7!)3IL0'()09S6-!L\<JWB\30[\4:EQ[F=
MMT+B &G9L%.(1M+0R?P1-1(\3H2A;P["M2/W(?\@'GW=W>F#T!$*7E?2W&#-
MN_6%P"QH&!R =T9/[88*J-G:A)1T'3RX#-ZZ)/\9JFX\P#>+E? &%N@-;IU<
MHQM7)?X[G@DJ67P7-H8 -3 0&DPQ;]N&F,)AO4EB=Z?L[2)G6!( 25#!13O
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M9ZK9LQN'E63%RJHW#P\]EQW_ U!+ P04    "  I<SQ4$<4\O?LZ  " +0$
M$0   ')A9&YE=%]E>#DY,#$N:'1M[7UKD]S&D>WWB9C_@-6U%'8$9D12EFV)
M6FT,2<D:+2G2Y-@*WV_50'5WB0"JA<>TVK_^YLG,>J!G1N87DU<@-]8BV=T
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MI&P,YK^#W"!-Q8*$-W)00K:'HL3'Y^1(5@8;^%=4=F\;*%T$D>(N+O'W X_
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MJ??(A0WCF5^?T8K9.NF)W/*F7QTK'3&E2*DV2&+#(#P]R=05B>R9MA)S8F"
MY9;Q!".#'NB]Q,0U0&W:Z-!$Y8A0[?&CX3&SF\PV0:;K,28- 6#T.[]#9AJ6
MR59K5EOHPH&\[<8PCG@?_%W3T'#K@^AVFA&S:MRP5?<70^8DQ3J:.+OMX<9+
M9F8+ M&=W[/+-VYEPME4:6$Z>,F>((: 3 (]8>7T[RLSP($<V(!09]'U!:G6
MT77!MP^1IP:IP_/B]Q=3[;S8<>J*_B'H4=:>G!PV'$B(*ABWR+0JQSW@KBL
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MQQ!H^<@3&W.C9F1!<'JR(X-Z9-L;L3/-L:Y";$,R#2RB.&:3RQJ\Y)%$U64
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MCHLQFD-RG$5ULZ^6@8@E C-IA)XE"6]QE@R-Z_# ;BCU?1!S$C*"&& :9,&
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MWB0HE_D- C.68MJ*WH-L7 85,1^6*]@6<BRN&,++1=J'&$@,CL?Y4:R3HYJ
MLN7Q.N;!GC'6*IE5L$H][::U<"S%.V>Q/\0B]0J.B)+[@. F%/X>M?_AW@N9
M\!MMFY9#YG_LPTM,>"'K!OW!N[0]*.(K;/ (8DIE\%I2RDG B%)A(%CF)+!D
M9O>(R9W%N.V*!_?N?ZX"S 2= <L\HN A.JW2,L#P2+<\LOI1N\)$C\QL-Q1U
M;Y QK%*%Q-$(^8E,;2WH.<EI)0SNH/9-P"PA(A'],8?,IVM7I&0@0V9O&E2)
M(H;$W]&+?_CN5?3K.M:8_TN_)!N)#1/5TY[50S\)V/9V.X;4MQ3]!D2=&<_
MFY9E*A,\%?/"26E9%]Q+DFWTT&F'US9%%WA$&F@P,/V#:8SM '$MU"45MDJE
M[ "P+@!H!],RI'A;1D2WN-^*<L;WJ)00NL#S&T6HL?R(30I-WW)!K\ QO5.B
MQAG,/\R#;J),\^O%3#&_DZG0#(]B"TC+!P24(9MS8X]#/I$FD8G2,E)%OZ3<
MS+=3CU5NO3+U280CH'".'7W44ZB+$OU@WKL,><9D_SRYZG5ST-V7:MLXB'6!
M5?Z_M <J<^3"^Q5,?(8!! )3_AZ']FP8.4T?!R8CD=1\W4\;TJ(;VOV#S\Q
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M-LX1DSX5K=6C7,B.@B<MA3\V-N--3=PC6!9ZJ_9,:"H-29F'6K2R*'J,BVM
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MS]!6O+@O]$E,F*4]8'$%4P)9??OP-N7,G>:X" X/*U=E#"0GFGLX5 <.POG
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M17,4_W,X-9']K5&S4DVU_ -02P,$%     @ *7,\5/FN/4__"@  ;(<  !4
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MY-R@(@,D<_!&W44<BX.5E7^N$TJFX#&P:MT2UF&WR95%&!!-L#N H5+Y07]
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MO7^7V!48_88U(+ R"%!Z[9G B(!Q5(M *@05,?[1F6?9EO W 60)\801:!Z
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M1 TT:7)5A#5/O(M )"-]KZI47Y ?'O8U1(Y'RQ:#QF"YI@B"$] 6-%2NO]_
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M7SAK+FAT;5!+ 0(4 Q0    ( "ES/%01Q3R]^SH  ( M 0 1
M  "  1T4  !R861N971?97@Y.3 Q+FAT;5!+ 0(4 Q0    ( "ES/%0BA @O
M.0,  .\+   1              "  4=/  !R9&YT+3(P,C(P,3(W+GAS9%!+
M 0(4 Q0    ( "ES/%3YKCU/_PH  &R'   5              "  :]2  !R
M9&YT+3(P,C(P,3(W7VQA8BYX;6Q02P$"% ,4    "  I<SQ47VM"\5('  "]
M6   %0              @ 'A70  <F1N="TR,#(R,#$R-U]P<F4N>&UL4$L%
3!@     %  4 /P$  &9E      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
